AIMS: @entity417 of @entity32 is quite prevalent in hospitalized @entity1 with poor prognosis. Concerns about the effectiveness and safety of @entity68 supplementation have arisen, driving the demand for alternative therapies. Induction of @entity99 , the master hormone of @entity68 homeostasis, causes @entity417 under inflammatory conditions. Previous studies indicated that @entity3957 ( @entity3958 ), the third gasotransmitter and a well-known regulator of @entity32 , may inhibit the secretion of inflammatory cytokines. We thus investigated the effect of @entity3958 on inflammatory hepcidin induction. RESULTS: @entity3958 suppressed lipopolysaccharide (LPS)-induced hepcidin production and regulated @entity68 homeostasis in @entity19 by decreasing serum @entity777 ( @entity777 ) and @entity16404 ( @entity16404 )/ @entity10433 ( @entity10433 ) activation; similar results were obtained in Huh7 cells exposed to conditioned medium from LPS-challenged THP-1 macrophages. Intriguingly, we found @entity3958 also attenuated hepcidin levels in Huh7 cells and @entity19 primary hepatocytes in a @entity14075 ( @entity14075 )-dependent manner. By promoting @entity14075 expression and stabilizing @entity14075 - @entity10433 interactions, @entity3958 ameliorated @entity777 -induced @entity10433 acetylation, resulting in reduced hepcidin production. Inhibition and silencing of @entity14075 diminished @entity3958 -mediated suppression of hepcidin, as opposed to @entity14075 activation and overexpression. Consistent results were observed in vivo. Furthermore, knockout of @entity3959 y-lyase (CSE), an endogenous @entity3958 synthase, exaggerated inflammatory hepcidin expression in @entity19 . INNOVATION: For the first time, we elucidated the effects and possible mechanisms of @entity3958 on inflammatory hepcidin and established a novel regulatory link between @entity14075 and hepcidin. CONCLUSION: Our work demonstrates that @entity3958 attenuates @entity32 -induced @entity99 via multipathways and suggests new treatment strategies for @entity417 of @entity32 . Antioxid. Redox Signal. 24, 70-83.

@entity3957 Attenuates Inflammatory Hepcidin by Reducing @entity777 Secretion and Promoting XXXX -Mediated @entity10433 Deacetylation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity3958 :: ('CHEBI:36945', 'Chemical') :: ['H2S'] @entity16404 :: ('16452(Tax:10090)', 'Gene') :: ['Janus kinase 2', 'JAK2'] @entity417 :: ('MESH:D000740', 'Disease') :: ['Anemia', 'anemia'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity3959 :: ('MESH:D003540', 'Chemical') :: ['cystathionine'] @entity10433 :: ('20848(Tax:10090)', 'Gene') :: ['STAT3', 'signal transducer and activator of transcription 3'] @entity777 :: ('16193(Tax:10090)', 'Gene') :: ['interleukin-6', 'IL-6'] @entity14075 :: ('93759(Tax:10090)', 'Gene') :: ['sirtuin 1', 'SIRT1'] @entity3957 :: ('MESH:D006862', 'Chemical') :: ['hydrogen sulfide'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic hepcidin'] @entity68 :: ('MESH:D007501', 'Chemical') :: ['iron']
@entity14075 :: (93759(Tax:10090),Gene) :: ['SIRT1']
